(ROP) Roche Holding - SW
Sector: Healthcare | Industry: Drug Manufacturers - General | Exchange: SW (Switzerland) | Market Cap: 262.554m CHF | Total Return: 27.8% in 12m
Avg Turnover: 321M
Rev. Trend: 63.0%
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Roche Holding AG is a global healthcare company headquartered in Basel, Switzerland, operating through two primary divisions: Pharmaceuticals and Diagnostics. The company develops treatments for a wide range of therapeutic areas, including oncology, immunology, and neuroscience, while simultaneously providing in vitro diagnostic solutions and digital health tools. This integrated business model allows the firm to leverage synergies between drug development and diagnostic testing, a strategy often referred to as personalized healthcare.
The pharmaceutical industry is characterized by high research and development costs and long regulatory approval cycles, making intellectual property and pipeline depth critical for long-term sustainability. As a mega-cap entity, Roche maintains a significant global footprint across six continents, focusing on specialty medicines that often command higher margins than generic alternatives. You may find further insights into the companys valuation metrics by exploring ValueRay.
- Vabysmo and Ocrevus sales volume offsets biosimilar erosion of legacy oncology
- Obesity pipeline clinical data milestones drive valuation and investor sentiment
- Diagnostics division margins stabilize following decline in COVID-19 testing demand
- R&D productivity and M&A execution replenish late-stage immunology and neurology pipelines
| Net Income: 12.9b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA -3.99 > 1.0 |
| NWC/Revenue: 17.44% < 20% (prev 20.86%; Δ -3.42% < -1%) |
| CFO/TA 0.18 > 3% & CFO 17.8b > Net Income 12.9b |
| Net Debt (17.7b) to EBITDA (22.7b): 0.78 < 3 |
| Current Ratio: 1.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (803.0m) vs 12m ago -0.12% < -2% |
| Gross Margin: 73.53% > 18% (prev 73.90%; Δ -0.37% > 0.5%) |
| Asset Turnover: 60.76% > 50% (prev 61.29%; Δ -0.54% > 0%) |
| Interest Coverage Ratio: 14.28 > 6 (EBIT TTM 19.3b / Interest Expense TTM 1.35b) |
| A: 0.11 (Total Current Assets 38.7b - Total Current Liabilities 28.0b) / Total Assets 101b |
| B: 0.48 (Retained Earnings 48.8b / Total Assets 101b) |
| C: 0.19 (EBIT TTM 19.3b / Avg Total Assets 101b) |
| D: 0.54 (Book Value of Equity 33.8b / Total Liabilities 62.8b) |
| Altman-Z'' = 4.12 = AA |
| DSRI: 0.89 (Receivables 11.9b/13.5b, Revenue 61.5b/62.4b) |
| GMI: 1.01 (GM 73.90% / 73.53%) |
| AQI: 1.04 (AQ_t 0.39 / AQ_t-1 0.37) |
| SGI: 0.99 (Revenue 61.5b / 62.4b) |
| TATA: -0.05 (NI 12.9b - CFO 17.8b) / TA 101b) |
| Beneish M = -3.10 (Cap -4..+1) = AA |
As of June 17, 2026, the stock is trading at CHF 324.00 with a total of 881,895 shares traded.
Over the past week, the price has changed by +1.05%,
over one month by +1.02%,
over three months by +1.18% and
over the past year by +27.84%.
Roche Holding has no consensus analysts rating.
P/E Trailing = 20.5736
P/E Forward = 16.2075
P/S = 4.1441
P/B = 7.7674
P/EG = 1.4462
Revenue TTM = 61.5b CHF
EBIT TTM = 19.3b CHF
EBITDA TTM = 22.7b CHF
Long Term Debt = 27.4b CHF (from longTermDebt, last quarter)
Short Term Debt = 4.21b CHF (from shortTermDebt, last quarter)
Debt = 33.2b CHF (from shortLongTermDebtTotal, last quarter) + Leases 1.55b
Net Debt = 17.7b CHF (calculated: Debt 33.2b - CCE 15.5b)
Enterprise Value = 280b CHF (263b + Debt 33.2b - CCE 15.5b)
Interest Coverage Ratio = 14.28 (Ebit TTM 19.3b / Interest Expense TTM 1.35b)
EV/FCF = 23.61x (Enterprise Value 280b / FCF TTM 11.9b)
FCF Yield = 4.24% (FCF TTM 11.9b / Enterprise Value 280b)
FCF Margin = 19.30% (FCF TTM 11.9b / Revenue TTM 61.5b)
Net Margin = 20.94% (Net Income TTM 12.9b / Revenue TTM 61.5b)
Gross Margin = 73.53% ((Revenue TTM 61.5b - Cost of Revenue TTM 16.3b) / Revenue TTM)
Gross Margin QoQ = 72.93% (prev 74.13%)
Tobins Q-Ratio = 2.78 (Enterprise Value 280b / Total Assets 101b)
Interest Expense / Debt = 4.06% (Interest Expense 1.35b / Debt 33.2b)
Taxrate = 18.70% (3.17b / 17.0b)
NOPAT = 15.7b (EBIT 19.3b * (1 - 18.70%))
Current Ratio = 1.38 (Total Current Assets 38.7b / Total Current Liabilities 28.0b)
Debt / Equity = 0.98 (Debt 33.2b / totalStockholderEquity, last quarter 33.8b)
Debt / EBITDA = 0.78 (Net Debt 17.7b / EBITDA 22.7b)
Debt / FCF = 1.49 (Net Debt 17.7b / FCF TTM 11.9b)
Total Stockholder Equity = 30.8b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.72% (Net Income 12.9b / Total Assets 101b)
RoE = 41.82% (Net Income TTM 12.9b / Total Stockholder Equity 30.8b)
RoCE = 33.08% (EBIT 19.3b / Capital Employed (Equity 30.8b + L.T.Debt 27.4b))
RoIC = 21.21% (NOPAT 15.7b / Invested Capital 73.8b)
WACC = 5.83% (E(263b)/V(296b) * Re(6.15%) + D(33.2b)/V(296b) * Rd(4.06%) * (1-Tc(0.19)))
Discount Rate = 6.15% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -58.20 | Cagr: -3.10%
[DCF] Terminal Value 73.10% ; FCFF base≈13.6b ; Y1≈11.9b ; Y5≈9.60b
[DCF] Fair Price = 198.0 (EV 154b - Net Debt 17.7b = Equity 136b / Shares 688.9m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
Revenue Correlation: 63.05 | Revenue CAGR: 1.71% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=20.19 | Chg30d=+0.71% | Revisions=+0% | GrowthEPS=+3.8% | GrowthRev=+1.7%
EPS next Year (2027-12-31): EPS=21.79 | Chg30d=+0.09% | Revisions=+20% | GrowthEPS=+7.9% | GrowthRev=+4.1%
[Analyst] Revisions Ratio: +20%